// App-Quantinova.ai

609 : Retrospective analysis of toxicity in patients (pts) with liver metastases (mets) from phase 3 studies of trastuzumab emtansine (T-DM1) in pts with metastatic breast cancer (MBC).

Researchers

Presenter

  • David Miles

Principal Investigators

  • Hans Wildiers

  • Mark D. Pegram

  • Nadia Harbeck

  • Marjorie C. Green

  • Meghna Samant

Medical Centers

  • Breast Center, University of Munich, Munich, GermanyGenentech, Inc., South San Francisco, CAStanford Cancer Institute, Palo Alto, CA

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

Locations

  • United States

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Secondary liver cancer

  • Solid malignancies

Biomarkers

  • Alanine transaminase

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • Positive

Study Design

  • randomized

Phase

  • III

Study Id's

  • NCT00829166

Sponsors

  • Genentech

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved